2022
The PRECEDE consortium: A longitudinal international cohort study of individuals with genetic risk or familial pancreatic cancer.
Zogopoulos G, Bi Y, Brand R, Chung D, Earl J, Farrell J, Graff J, Kastrinos F, Katona B, Klute K, Koptiuch C, Kupfer S, Kwon R, Lindberg J, Lowy A, Lucas A, Paiella S, Permuth J, Sears R, Simeone D, Consortium T. The PRECEDE consortium: A longitudinal international cohort study of individuals with genetic risk or familial pancreatic cancer. Journal Of Clinical Oncology 2022, 40: e16239-e16239. DOI: 10.1200/jco.2022.40.16_suppl.e16239.Peer-Reviewed Original ResearchPancreatic ductal adenocarcinomaPathogenic germline variantsFamilial pancreatic cancerCancer predisposition genesCohort studyPancreatic cancerClinical dataAnnual surveillanceEffective early detection strategiesHigh-quality clinical dataHigh-risk premalignant lesionsModifiers of riskInternational cohort studyProspective cohort studyEarly-stage diseaseOverall survival rateEarly detection strategiesEarly-stage cancerBlood sample collectionRelevant clinical populationContribution of heritabilityPenetrance of diseaseQuality clinical dataParticipants ages 18Germline testing
2020
Pancreatic Cancer; Biomolecular and Genetic Aspects
Yoo J, Farrell J. Pancreatic Cancer; Biomolecular and Genetic Aspects. 2020, 30-38. DOI: 10.1016/b978-0-12-801238-3.65864-6.Peer-Reviewed Original ResearchPancreatic cancerGenetic aspectsNext-generation sequencingTranscriptomic analysisGenomic investigationsKey driver mutationsRecent translational advancesOverall survival rateMutational landscapeDiscrete molecular subtypesGeneration sequencingSpecific therapyLethal malignancyMolecular subtypesDisease processDriver mutationsSurvival rateTranslational advancesCancerPrecision medicineBiomolecularSequencingMutationsPathwayPatients